On October 8, WUXI APPTEC fell 3.11% in regular trading, touching 211.6 Hong Kong dollars with turnover reaching 9.35 billion Hong Kong dollars. The decline came as the Hong Kong pharmaceutical and biotechnology sector faced broad-based selling pressure.
Among sector peers, GENSCRIPT BIO dropped 4.1%, WUXI BIO fell 3.79%, INSILICO tumbled 8.19%, XTALPI lost 1.92%, and WUXI XDC declined 2.14%. The CXO and innovative drug space generally traded lower, dragging down WUXI APPTEC.
The stock had previously rallied on multiple catalysts including full conversion of convertible bonds, institutional accumulation by FMR LLC and JPMorgan, and improving CXO sector fundamentals. After reaching a historical high of 219.2 Hong Kong dollars on October 7, short-term profit-taking pressure emerged, contributing to the current pullback.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)